- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Hyloris Developmentsen Sa (HYL)Hyloris Developmentsen Sa stock price live, this page displays EBR HYL stock exchange data. View the HYL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Hyloris Developmentsen Sa real time stock price chart below.
What Is the Hyloris Developmentsen Sa Stock Price Today?
The Hyloris Developmentsen Sa stock price today is 5.40.
What Is the Stock Symbol for Hyloris Developmentsen Sa?
The stock symbol for Hyloris Developmentsen Sa is "HYL."
What Stock Exchange Does Hyloris Developmentsen Sa Trade On?
Hyloris Developmentsen Sa is listed and trades on the Brussels stock exchange.
Is Hyloris Developmentsen Sa a Good Stock to Buy?
Determining whether Hyloris Developmentsen Sa—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HYL quote. (ISIN: BE0974363955)
What Is the Hyloris Developmentsen Sa Stock Price Today?
The Hyloris Developmentsen Sa stock price today is 5.40.
What Is the Stock Symbol for Hyloris Developmentsen Sa?
The stock symbol for Hyloris Developmentsen Sa is "HYL."
What Stock Exchange Does Hyloris Developmentsen Sa Trade On?
Hyloris Developmentsen Sa is listed and trades on the Brussels stock exchange.
Is Hyloris Developmentsen Sa a Good Stock to Buy?
Determining whether Hyloris Developmentsen Sa—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HYL quote. (ISIN: BE0974363955)
Brussels
Currency in EUR
5.40
+0.08(+1.50%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.26
5.50
52 wk Range
2.89
13.30
HYL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.265.50
52 wk Range
2.8913.30
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockHYL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Price Target
11.10
Upside
+105.56%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Hyloris Company Profile
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. In addition, the company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream for recurrent vulvovaginal candidiasis; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; and HY-091 for vulvar lichen sclerosis. The company was incorporated in 2012 and is headquartered in Liège, Belgium.
Compare HYL to Peers and Sector
Metrics to compare | HYL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHYLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.4x | −6.1x | −0.6x | |
PEG Ratio | 2.92 | −0.02 | 0.00 | |
Price/Book | 4.4x | 0.4x | 2.6x | |
Price / LTM Sales | 21.8x | 2.3x | 3.2x | |
Upside (Analyst Target) | 107.1% | 64.1% | 44.6% | |
Fair Value Upside | Unlock | 12.2% | 7.3% | Unlock |
Analysts' Recommendations
1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 11.10
(+105.56% Upside)
FAQ
What Is the Hyloris (HYL) Stock Price Today?
The Hyloris stock price today is 5.40.
What Stock Exchange Does Hyloris Trade On?
Hyloris is listed and trades on the Brussels stock exchange.
What Is the Stock Symbol for Hyloris?
The stock symbol for Hyloris is "HYL."
What Is the Hyloris Market Cap?
As of today, Hyloris market cap is 151.20M.
What is Hyloris Earnings Per Share?
The Hyloris EPS is -0.465.
From a Technical Analysis Perspective, Is HYL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.